

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Perier Francis I Jr</u> <hr/> (Last) (First) (Middle) C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. <hr/> (Street) STAMFORD CT 06902 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SpringWorks Therapeutics, Inc. [ SWTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ <b>Chief Financial Officer</b>
	3. Date of Earliest Transaction (Month/Day/Year) 01/04/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock <sup>(1)</sup>	01/04/2024		A <sup>(1)</sup>		21,156 <sup>(1)</sup>	A	\$0.00	64,619	D	
Common Stock	01/05/2024		F <sup>(2)</sup>		2,151 <sup>(2)</sup>	D	\$37.96	62,468	D	
Common Stock	01/08/2024		F <sup>(2)</sup>		3,215 <sup>(2)</sup>	D	\$41.53	59,253	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$38.4	01/04/2024		A		60,000		(3)	01/03/2034	Common Stock	60,000	\$0	60,000	D	

**Explanation of Responses:**

- This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date.
- Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person.
- This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date.

/s/ Francis I. Perier, Jr. 01/08/2024  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.